Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga/177Lu-PSMA theranostics in recurrent high-grade glioma
2024-518495-31-00Phase 2Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lu-PNT2002 in glioma, sponsored by Norwegian University of Science and Technology. Primary endpoints: Safety and tolerability, Progression-free survival at 6 months and 1 more. Started Oct 2024; status: completed.
02
Drugs
Lu-PNT2002
03
Conditions
glioma
Beyond the preview
Go deeper on 2024-518495-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518495-31-00.